

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A specific binding member that binds human ED-B and which comprises an antigen-binding site that comprises an antibody VH domain and an antibody VL domain, wherein the antibody VH domain is selected from the group consisting of the L19 VH domain, and a VH domain comprising a VH CDR1, a VH CDR2 and a VH CDR3, wherein the VH CDR3 is the L19 VH CDR3 of SEQ ID NO. 3, the VH CDR1 is optionally L19 VH CDR1 of SEQ ID NO. 1, and the VH CDR2 is optionally L19 VH CDR2 of SEQ ID NO. 2; and wherein the antibody VL domain is optionally selected from the group consisting of the L19 VL domain, and a VL domain comprising a VL CDR1, a VL CDR2 and a VL CDR3, wherein the VL CDR3 is the L19 VL CDR3 of SEQ ID NO. 6, the VL CDR1 is optionally L19 VL CDR1 of SEQ ID NO. 4, and the VL CDR2 is optionally L19 VL CDR2 of SEQ ID NO. 5; the L19 VH domain and L19 VL domain sequences being disclosed in Pini et al. (1998) *J. Biol. Chem.* 273: 21769-21776; wherein the specific binding member comprises a mini-immunoglobulin comprising said antibody VH domain and antibody VL domain fused to  $\epsilon_{S2}$ -CH4 and dimerized or comprises a whole IgG1 antibody molecule.
2. (Original) A specific binding member according to claim 1 comprising an antibody VH domain comprising the VH CDR's with the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, which specific binding member competes for binding to ED-B with an ED-B-binding domain of an antibody comprising the L19 VH domain and the L19 VL domain.
3. (Currently Amended) A specific binding member according to claim 1 ~~or claim 2~~ comprising the L19 VH domain.
4. (Original) A specific binding member according to claim 3 comprising the L19 VL domain.
5. (Currently Amended) A specific binding member according to ~~any one of the~~

~~preceding claims~~ claim 1 which is a mini-immunoglobulin comprising  $\epsilon_{S2}$ -CH4.

6. (Original) A specific binding member according to claim 5 wherein the antibody VH domain and antibody VL domain are within an scFv antibody molecule fused to  $\epsilon_{S2}$ -CH4.

7. (Original) A specific binding member according to claim 6 wherein the scFv antibody molecule is fused to  $\epsilon_{S2}$ -CH4 via a linker peptide.

8. (Original) A specific binding member according to claim 7 wherein the linker peptide has the amino acid sequence GGSG (SEQ ID NO. 7).

9. (Currently Amended) A specific binding member according to ~~any one of claims 1 to 4~~ claim 1 that comprises a whole IgG1 antibody molecule.

10. (Currently Amended) A specific binding member according to ~~any of claims 1 to 9~~ claim 1 which is conjugated to a radioisotope

11. (Original) A specific binding member according to claim 10 wherein the radioisotope is a radioisotope of Tc, Re, In, Y or Lu.

12. (Original) A specific binding member according to claim 10 wherein the radioisotope is selected from the group consisting of  $^{94m}\text{Tc}$ ,  $^{99m}\text{Tc}$ ,  $^{186}\text{Re}$ ,  $^{203}\text{Pb}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{43}\text{Sc}$ ,  $^{47}\text{Sc}$ ,  $^{110m}\text{In}$ ,  $^{111}\text{In}$ ,  $^{97}\text{Ru}$ ,  $^{62}\text{Cu}$ ,  $^{64}\text{Cu}$ ,  $^{67}\text{Cu}$ ,  $^{68}\text{Cu}$ ,  $^{86}\text{Y}$ ,  $^{88}\text{Y}$ ,  $^{90}\text{Y}$ ,  $^{121}\text{Sn}$ ,  $^{161}\text{Tb}$ ,  $^{153}\text{Sm}$ ,  $^{166}\text{Ho}$ ,  $^{105}\text{Rh}$ ,  $^{177}\text{Lu}$ ,  $^{172}\text{Lu}$  and  $^{18}\text{F}$ .

13. (Currently Amended) An isolated nucleic acid which comprises a nucleotide sequence or nucleotide sequences encoding a specific binding member according to ~~any one of claims 1 to 9~~ claim 1.

14. (Original) A host cell transformed with nucleic acid according to claim 13.

15. (Original) A method of producing a specific binding member, the method comprising

culturing host cells according to claim 14 under conditions for production of said specific binding member.

16. (Original) A method according to claim 15 further comprising isolating and/or purifying said specific binding member.

17. (Currently Amended) A method according to claim 15 ~~or claim 16~~ further comprising formulating the specific binding member into a composition including at least one additional component.

18. (Currently Amended) A method according to ~~any one of claims 15 to 17~~ claim 15 further comprising binding the specific binding member to ED-B or a fragment of ED-B.

19. (Currently Amended) A method comprising binding a specific binding member that binds ED-B according to ~~any one of claims 1 to 9~~ claim 1 to ED-B or a fragment of ED-B.

20. (Currently Amended) A method according to claim 18 ~~or claim 19~~ wherein said binding takes place *in vitro*.

21. (Currently Amended) A method according to ~~any one of claims 18 to 20~~ claim 18 comprising determining the amount of binding of specific binding member to ED-B or a fragment of ED-B.

22. (Currently Amended) A composition comprising a specific binding member according to ~~any one of claims 1 to 9~~ claim 1, for use in a method of treatment of the human or animal body by therapy.

23. (Original) A composition according to claim 22 for use in a method of treatment of a lesion of pathological angiogenesis.

24. (Original) A composition according to claim 22 for use in a method of treatment of a

tumor.

25. (Currently Amended) ~~Use of a specific binding member according to any one of claims 1 to 9 in the manufacture of a medicament~~ A method for treating a lesion of pathological angiogenesis comprising administering a specific binding member of claim 1.

26. (Currently Amended) ~~Use of~~ A method ~~a specific binding member according to any one of claims 1 to 9 in the manufacture of a medicament~~ for treating a tumor comprising administering a specific binding member of claim 1.